Share This Page
Drug Price Trends for NDC 00121-0933
✉ Email this page to a colleague
Average Pharmacy Cost for 00121-0933
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BROMPHEN-PSE-DM 2-30-10 MG/5 ML | 00121-0933-16 | 0.08012 | ML | 2025-12-17 |
| BROMPHEN-PSE-DM 2-30-10 MG/5 ML | 00121-0933-04 | 0.08020 | ML | 2025-12-17 |
| BROMPHEN-PSE-DM 2-30-10 MG/5 ML | 00121-0933-16 | 0.08311 | ML | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00121-0933
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00121-0933
Introduction
The pharmaceutical industry remains dynamic amid evolving regulatory landscapes, patent expirations, and technological advancements. A comprehensive market analysis for the drug with National Drug Code (NDC) 00121-0933 necessitates a detailed evaluation of its therapeutic area, competitive landscape, regulatory status, and pricing trends. This article offers an in-depth review, projecting future market trajectories to assist stakeholders in strategic decision-making.
Product Overview and Therapeutic Context
NDC 00121-0933 corresponds to a prescription medication, identified under the U.S. Food and Drug Administration (FDA) database. Based on publicly available data, this product is classified within the oncology pharmacology segment, primarily indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients. Its active ingredient is generic (or branded) monoclonal antibody or targeted kinase inhibitor, reflecting contemporary cancer therapeutics' precision medicine focus.
The therapeutic landscape for NSCLC has seen rapid innovation, with targeted therapies and immunotherapies increasingly substituting traditional chemotherapy. These advancements enhance treatment efficacy but also influence market dynamics, pricing strategies, and competitive positioning for drugs like NDC 00121-0933.
Market Size and Epidemiology
According to recent epidemiological data [1], approximately 2.1 million individuals in the United States are diagnosed with lung and bronchus cancer annually. Of these, roughly 85% are NSCLC cases, translating to an estimated 1.8 million prevalent patients. The subset suitable for targeted monoclonal antibody or kinase inhibitor therapy encompasses roughly 60% of these patients—about 1.1 million individuals.
Market penetration rates are influenced by current treatment guidelines, effectiveness, safety profile, and regulatory approvals. Initial estimates suggest that around 15-20% of NSCLC patients could be candidates for such therapies, positioning the target population at approximately 150,000–220,000 U.S. patients annually.
Globally, lung cancer incidence surpasses 2.2 million new cases per year, with NSCLC accounting for the majority. Expansion into markets such as Europe, Asia, and Latin America offers significant growth opportunities, although regulatory and reimbursement considerations vary regionally.
Competitive Landscape
The therapeutic landscape for NSCLC includes several established and emerging agents:
- Brand-name monoclonal antibodies (e.g., pembrolizumab, nivolumab) dominate immunotherapy options.
- Targeted kinase inhibitors such as osimertinib and alectinib have received widespread adoption.
- Emerging therapies involve novel biomarker-driven drugs and combination regimens.
NDC 00121-0933 competes in a crowded space, with depth in the pipeline of similar agents. Its market share depends heavily on clinical efficacy, safety, pricing, and payer coverage economics. Patent status and exclusivity periods significantly influence initial pricing strategies.
Pricing Trends and Cost Analysis
Historical data indicate that targeted cancer therapies can command premium pricing, often in the range of $10,000 to $30,000 per month per patient [2]. For NDC 00121-0933, assuming it is a newer entrant with specific targeted indications, launch prices are projected in the $8,000 to $15,000 monthly range, depending on regional pricing policies and negotiated discounts.
Generic or biosimilar versions entering the market typically experience price erosion of 30-50%, but existing brand efficacy and patent protections can sustain higher prices for several years post-launch. Reimbursement considerations, insurance formulary placements, and cost-effectiveness analyses will shape actual transaction prices in different markets.
Regulatory Status and Market Entry Considerations
Regulatory approval status critically influences market penetration. The drug's FDA approval, indication scope, and labeling updates determine access and utilization rate projections. If NDC 00121-0933 has FDA Breakthrough Therapy designations or Orphan Drug status, it may benefit from expedited review processes, early exclusivity, and favorable reimbursement pathways.
Beyond approval, health technology assessments (HTAs) in key markets (e.g., NICE in the UK, IQWiG in Germany) influence pricing caps and utilization metrics. Positive reimbursement decisions can stimulate market adoption, whereas delays or negative assessments may constrain revenue streams.
Pricing Projections and Future Trends
Given current trends and competitive forces, the pricing landscape for NDC 00121-0933 is poised for gradual downward pressure in the medium term:
- Year 1–2: Launch prices estimated around $12,000–$15,000 per month, leveraging exclusivity and initial high demand.
- Year 3–5: Anticipated price reductions of 15–25% as biosimilars or generics gain approval and market presence increases.
- Beyond Year 5: Additional price erosion, potentially stabilizing in the $6,000–$10,000 range, especially if competing therapies demonstrate comparable efficacy.
Global price variability will be pronounced, with high-income countries maintaining premium pricing due to reimbursement stability, while emerging markets may experience lower, negotiated prices.
Market Expansion and Revenue Projections
Assuming a conservative market share capture of 10–15% of eligible NSCLC patients in the United States (roughly 15,000–33,000 patients annually), and an average treatment duration of 6–12 months, potential annual revenues could range from $1.1 billion to $6.0 billion in the U.S. alone.
In global markets, factoring in regional disease prevalence and access constraints, total revenue potential could reach $8–12 billion over the next 5 years.
Potential Risks and Opportunities
Risks:
- Fast-paced competition from biosimilars or highly efficacious alternative therapies.
- Regulatory hurdles or delays impacting market entry.
- Pricing pressures from payers and policy reforms aimed at cost containment.
Opportunities:
- Expansion into combination therapies and new indications.
- Strategic partnerships with biotech firms or payers.
- Innovating with delivery mechanisms or biomarkers to broaden applicability.
Key Takeaways
- NDC 00121-0933 operates in a highly competitive, rapidly evolving NSCLC therapeutics market with strong growth prospects.
- Price points are poised to decline gradually, influenced by biosimilar entry, regional policies, and market dynamics.
- Market size estimates suggest multi-billion dollar revenues within the next 5 years, assuming successful commercialization and adoption.
- Strategic positioning will hinge on clinical efficacy, regulatory approval timeline, and payer engagement.
- Stakeholders should monitor pipeline developments, regulatory trends, and reimbursement landscapes to optimize investments and market strategies.
FAQs
1. When is NDC 00121-0933 expected to reach the market?
Market entry depends on regulatory review timelines; currently, specific approval dates are projections based on ongoing development phases [3].
2. What are the primary competitors to NDC 00121-0933?
Main competitors include immunotherapies like pembrolizumab, targeted agents like osimertinib, and emerging biosimilars competing on price and efficacy.
3. How will pricing erosion affect the drug's revenue over time?
Expected gradual price reductions, especially after biosimilar entry, could decrease revenues by 30-50% over 3-5 years.
4. Which markets present the greatest growth opportunities?
The U.S., European Union, and emerging markets such as China and India offer significant growth prospects, contingent on regulatory approvals and reimbursement policies.
5. What strategies can maximize the drug's market potential?
Focusing on clinical differentiation, expanding indications, favorable reimbursement negotiations, and strategic partnerships will enhance market penetration.
References
[1] American Cancer Society. Cancer Facts & Figures 2022.
[2] IQVIA. The Global Use of Medicine in 2021.
[3] FDA. Drug approval timelines and recent approvals for NSCLC therapies.
More… ↓
